Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates

A scientist at RNA medicines company Arcturus Therapeutics researches a vaccine for the novel coronavirus (COVID-19) at a laboratory in San Diego.
ReutersArcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Analysts from Barclays, Raymond James, and Baird all downgraded their ratings for Arcturus on Tuesday. Arcturus released clinical and precl